The new 2019 AMNOG-MONITOR

Early benefit assessment overview

- Analyses of all G-BA early benefit assessment resolutions updated on a monthly basis
- An absolute must for doers, managers and decision-makers, especially from the fields of market access, pricing and reimbursement, medicine, business development and legal affairs
- Access the AMNOG Monitor from anywhere – from the office, a meeting, the train, the airport or home
- Access for 10 people for one price

Analysis and review of all G-BA resolutions

The new 2019 AMNOG monitor is updated on a monthly basis.

Each edition features:

- Structured analysis of each individual G-BA resolution (over 350 decisions) plus lessons learnt for each case
- Overview of the G-BA’s decision-making practice
- Comparison of all decisions: pharmaceutical manufacturer’s objectives, IQWiG assessment and G-BA resolution
- Evaluation and analysis for 7 indications
- Management presentation on the current status of early benefit assessment (English-language PowerPoint presentation, approx. 80 slides)
- Overview of the German healthcare system (English-language PowerPoint presentation, approx. 50 slides)
- Pricing contract analysis (list price vs. reimbursement price) Excel spreadsheet and visual overview of price development
- All files available as print-ready PDFs

Get free trial access: www.amnog-monitor.com

The qualitative and quantitative analysis of all G-BA early benefit assessment resolutions is compiled by Dr Johannes Hankowitz, Institut für Pharmakologie und präventive Medizin (IPPMed) in cooperation with Dr Olaf Pirk. It allows you to analyse trends and decisions so that you can determine the optimal strategy for your medicinal product’s reimbursement.

Contact us:

We would be happy to inform and advise you!
Contact:
Dr. Johannes Hankowitz
Institut für Pharmakologie und präventive Medizin (IPPMed)
Adelsbergstraße 23 · D-81247 Munich
Phone: +49 89-18948312
E-mail: hankowitz@ippmed.de
IPPMed partnership supports you throughout the whole early benefit assessment procedure

- Advice on conducting clinical studies (e.g. design, comparators and end points)
- Identification of patient-relevant end points based on findings from all AMNOG procedures
- Support in planning and conducting G-BA consultations and/or joint scientific advice
- Advice on the compilation of value dossiers in accordance with Section 35a of the German Social Code (Sozialgesetzbuch – SGB), Book Five (modules 1 to 5)
- Drafting of positions in preparation for G-BA hearings
- Strategy development for price negotiations with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband)

Contact us:
Dr. Johannes Hankowitz
Institut für Pharmakologie und präventive Medizin
Adelsbergstraße 23 · D-81247 Munich
Phone: + 49 89-18948312
E-mail: hankowitz@ippmed.de

Interactive online analysis tool
www.amnog-monitor.com

Early benefit assessment analysis

- Interactive analysis tool to help you answer your questions
- Can be used from anywhere: PC, laptop, tablet computer, smartphone
- New monthly analyses from 2019, including:
  - G-BA reassessments (upon expiry of marketing authorisation or due to new scientific data, orphan drugs with revenues exceeding EUR 50 million, loss of orphan drug status)
  - Paediatric-use marketing authorisation (PUMA)
  - Advanced therapy medicinal products (ATMP)
  - Evidence transfer from adults to children
  - Bilingual: English/German

Advice on the compilation of value dossiers
in accordance with Section 35a of the German Social Code (Sozialgesetzbuch – SGB), Book Five

Interactive online analysis tool: www.amnog-monitor.com

- Interactive analysis tool to help you answer your questions
- Can be used from anywhere: PC, laptop, tablet computer, smartphone
- New monthly analyses from 2019, including:
  - G-BA reassessments (upon expiry of marketing authorisation or due to new scientific data, orphan drugs with revenues exceeding EUR 50 million, loss of orphan drug status)
  - Paediatric-use marketing authorisation (PUMA)
  - Advanced therapy medicinal products (ATMP)
  - Evidence transfer from adults to children
  - Bilingual: English/German